<PAGE> 1
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 12b-25
Commission File Number 000-21141
---------
NOTIFICATION OF LATE FILING
(Check One):
[ ] Form 10-K [ ] Form 11-K [ ] Form 20-F [X] Form 10-Q [ ] Form 10-N-SAR
For Period Ended: June 30, 2000
-------------
[ ] Transition Report on Form 10-K [ ] Transition Report on Form 10-Q
[ ] Transition Report on Form 20-F [ ] Transition Report on Form N-SAR
[ ] Transition Report on Form 11-K
For the Transition Period Ended: _______________________________________.
Nothing in this form shall be construed to imply that the Commission
has verified any information contained herein.
If the notification relates to a portion of the filing checked above,
identify the Item(s) to which the notification relates: ________________________
________________________________________________________________________________
PART I
REGISTRANT INFORMATION
Full Name of Registrant: PHARMAPRINT INC.
Former Name If Applicable: _____________________________________________________
Address of Principal Executive Office (Street and Number):
4701 VON KARMAN, SUITE 201
--------------------------------------------------------------------------------
City, State and Zip Code: NEWPORT BEACH, CA 92660
-----------------------------------------------------
PART II
RULE 12b-25(b) AND (c)
If the subject report could not be filed without unreasonable effort or
expense and the registrant seeks relief pursuant to Rule 12b-25(b), the
following should be completed. (Check appropriate box)
[ X ] (a) The reasons described in reasonable detail in Part III of this
form could not be eliminated without unreasonable effort or
expense;
[ X ] (b) The subject annual report, semi-annual report, transition
report on Form 10-K, 20-F, 11-K or Form N-SAR, or portion
thereof will be filed on or before the 15th calendar day
following the prescribed due date- or the subject quarterly
report or transition report on Form 10-Q, or portion thereof
will be filed on or before the fifth calendar day following
the prescribed due date; and
[ X ] (c) The accountant's statement or other exhibit required by Rule
12b-25(c) has been attached if applicable.
<PAGE> 2
PART III
NARRATIVE
State below in reasonable detail the reasons why Form 10-K, 11-K, 20-F,
10-Q, N-SAR or the transition report portion thereof could not be filed within
the prescribed time period. (Attach extra sheets if needed.)
The fiscal quarter of Pharmaprint Inc. (the "Company") ended on June 30,
2000. Accordingly, the Company's Periodic Report on Form 10-Q is required to be
filed by August 14, 2000.
On May 19, 2000, the Company dismissed Arthur Andersen LLP as its
independent accountants (the "Former Auditors") and engaged Corbin & Wertz as
the Company's independent accountants. Due to the date of the Company's
dismissal of the Former Auditors and the Company's engagement of Corbin & Wertz,
additional time is necessary for the newly engaged accountants to review the
Company's financial statements and complete the Company's Periodic Report on
Form 10-Q. Attached as Exhibit 1 hereto is a copy of Corbin & Wertz's statement.
The foregoing reasons causing the Company's inability to timely file its
Periodic Report on Form 10-Q for the fiscal quarter ended June 30, 2000 could
not be eliminated without unreasonable effort or expense.
PART IV
OTHER INFORMATION
(1) Name and telephone number of person to contact in regard to this
notification
Steven A. Bowman 949 794-7778
--------------------------------------------------------------------------------
(Name) (Area Code) (Telephone Number)
(2) Have all other periodic reports required under Section 13 or 15(d)
of the Securities Exchange Act of 1934 or Section 30 of the Investment Company
Act of 1940 during the preceding 12 months or for such shorter period that the
registrant was required to file such report(s) been filed? If the answer is no,
identify report(s).
[ ] Yes [ X ] No
The Company has not yet filed its annual report on form 10-K, but expects to
complete this filing within 5 calendar days of the date of this form 12b-25.
(3) Is it anticipated that any significant change in results of
operations from the corresponding period for the last fiscal year will be
reflected by the earnings statements to be included in the subject report or
portion thereof?
[ ] Yes [ X ] No
If so, attach an explanation of the anticipated change, both
narratively and quantitatively, and, if appropriate, state the reasons why a
reasonable estimate of the results cannot be made.
-2-
<PAGE> 3
PHARMAPRINT INC.
--------------------------------------------------------------------------------
(Name of Registrant as specified in Charter)
Has duly caused this notification to be signed on its behalf by the undersigned
thereunto duly authorized.
Date: August 14, 2000 By: /s/ Steven A. Bowman
--------------------------- ---------------------------------
Steven A. Bowman
Chief Executive Officer
-3-
<PAGE> 4
[CORBIN & WERTZ LETTERHEAD]
EXHIBIT 1
To Whom It May Concern:
Corbin & Wertz was unable to complete the SAS 71 review of PharmaPrint, Inc.
for the quarter ended June 30, 2000 due to unforeseen circumstances beyond the
company's control. We are in the process of completing such review for the
quarter ended June 30, 2000 and anticipate the review to be completed within the
prescribed time set forth in Rule 12b-25(b)(2)(ii).
/s/ CORBIN & WERTZ
-------------------------------------
Corbin & Wertz
-4-
